Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.18 EUR | +1.59% | +0.66% | +16.26% |
29/05 | Nicotine-like chemicals in U.S. vapes may be more potent than nicotine, FDA says | RE |
29/05 | Nicotine-like chemicals in U.S. vapes may be more potent than nicotine, FDA says | RE |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Tobacco
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.26% | 79.44B | - | ||
-7.71% | 63.79B | B | ||
+22.14% | 50.27B | A- | ||
-3.91% | 6.81B | A- | ||
-17.88% | 5.26B | A- | ||
-5.50% | 2.4B | C- | ||
-8.00% | 2.21B | C- | ||
-36.61% | 1.51B | - | ||
-2.82% | 1.3B | D+ | ||
-17.22% | 1.17B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MO Stock
- PHM7 Stock
- Ratings Altria Group, Inc.